Comanche Peak performs termination whole body counts and passive monitoring for 
all other routine counting.
 In-vitro analysis for tritium monitoring is performed for diving activities.
Lapel air samplers and whole body counting required for level III alpha areas.
In-vitro sampling required if CEDE based on lapel air sampler exceeds 5% ALI 
(250 mrem) from alpha.

Deb O'Connor
Comanche Peak
HP Supervisor
254-897-0151




From: [email protected] [mailto:[email protected]] On Behalf Of 
Holmes, Stephen J
Sent: Friday, March 30, 2012 12:49 PM
To: [email protected]
Subject: Powernet: Baseline Bioassay Sampling

I am looking at industry best practices for performing baseline and routine 
bioassay (in-vivo and in-vitro).

At Ginna we do not do baseline or routine/confirmatory WBCs, we take credit for 
our passive monitors (portal monitors) which are set to alarm at <1% ALI of the 
station DAW mixture.

We do have provisions in our procedures for performing in-vitro tritium 
bioassay prior to and after SFP diving activities.

We do not currently have guidance in our procedures for performing baseline or 
routine bioassay for workers who work in Alpha Level 3 / TRU areas. We do not 
often work in Alpha Level 3, but we do have a few areas that are characterized 
as such.

I do not know of any requirement to perform baseline or confirmatory in-vitro 
bioassay for workers potentially exposed to Alpha contamination. However, 
without performing in-vitro monitoring, the only thing we have to back up our 
Alpha contamination controls are job coverage surveys and air samples.

How do our practices line up with the rest of the industry?

Thanks,
-Steve

Stephen J Holmes, PE
Sr. Plant Health Physicist, CENG-RE Ginna NPP
[email protected]<mailto:[email protected]>
585-771-3577; 585-545-1661 (cell)


>>> This e-mail and any attachments are confidential, may contain legal, 
>>> professional or other privileged information, and are intended solely for 
>>> the addressee.  If you are not the intended recipient, do not use the 
>>> information in this e-mail in any way, delete this e-mail and notify the 
>>> sender. -IP1


Confidentiality Notice: This email message, including any attachments, 
contains or may contain confidential information intended only for the 
addressee. If you are not an intended recipient of this message, be advised 
that any reading, dissemination, forwarding, printing, copying or other use of 
this message or its attachments is strictly prohibited. If you have received 
this message in error, please notify the sender immediately by reply message 
and delete this email message and any attachments from your system. 

Reply via email to